Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 3, 2005

View Archived Issues

Completion of EVOLUTION-On safety trial of Angiomax

Novel vanilloid receptor-1 antagonists described for the treatment of pain

Telcyta ASSIST-1 trial completes enrollment, new ASSIST-3 trial under way

Ligand and TAP extend research collaboration

APC-8024 shows antitumor activity in patients with advanced breast cancer

Good efficacy and safety profile reported for Sch-66336 plus paclitaxel in metastatic breast cancer

Preclinical evidence for the antitumor efficacy of panitumumab in breast cancer

Riluzole shows promise in the management of depression and anxiety disorders

Update on the efficacy of mifepristone in psychotic major depression

CytoGenix takes stock of 2004

Phase II study investigates aerosolized amikacin for VAP

Fornix reviews R&D progress

Japanese phase IIb results for Proglia in acute cerebral infarction

Swedish approval for Tostrex

Newron claims glycoside derivatives and their use in Parkinson's, Alzheimer's, etc.

Antibacterial monoclonal antibodies described in patent literature

Five Aventis patents disclose novel antithrombotic agents

Sodium channel blockers for treatment of pain in early development at Merck

Standard and novel mGluR5 antagonists in the treatment of cocaine addiction

Novel small-molecule Bcl-2 inhibitor induces apoptosis in breast cancer cells

Discovery of a glucagon receptor antagonist for the treatment of diabetes

Phytomedicine EPs-7630 targets bacterial adhesion

Lyrica approved for diabetic peripheral neuropathy, postherpetic neuralgia